REGEN BIOLOGICS INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| - USD | -.--% |
|
-.--% | -.--% |
| Sales 2007 | 986K 1.35M | Sales 2008 | 1.37M 1.88M | Capitalization | 20.85M 28.46M |
|---|---|---|---|---|---|
| Net income 2007 | -10M -13.65M | Net income 2008 | -9M -12.29M | EV / Sales 2007 | 14 x |
| Net Debt 2007 | 4.09M 5.59M | Net Debt 2008 | 10.28M 14.04M | EV / Sales 2008 | 22.7 x |
| P/E ratio 2007 |
-0.9
x | P/E ratio 2008 |
-1.66
x | Employees | - |
| Yield 2007 * |
-
| Yield 2008 |
-
| Free-Float | 100% |
More Fundamentals
* Assessed data
More news
ReGen Biologics, Inc. (ReGen) is a development stage orthopedic products company that develops, manufactures and markets tissue growth and repair products for United States and global markets. The Company's collagen matrix technology includes applications in orthopedics, general surgery, spine, cardiovascular and drug delivery. Some of these applications are marketable while others are in various stages of development. ReGenâs first approved product using its collagen matrix technology is the Menaflex collagen meniscus implant device (also known as the CMI), which is marketed for sale in the European Union (EU), Switzerland, Turkey, and the Republic of South Africa, through the Companyâs subsidiary, ReGen Biologics AG.
| 1st Jan change | Capi. | |
|---|---|---|
| -.--% | 25 | |
| -2.31% | 187B | |
| -3.20% | 106B | |
| -5.04% | 66.9B | |
| +0.20% | 49.45B | |
| +17.29% | 48B | |
| +4.06% | 40.84B | |
| +2.07% | 26.48B | |
| +2.36% | 26.25B | |
| +12.96% | 24.62B |
- Stock Market
- Equities
- RGBOQ Stock
